The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma-Reference-Cited by-同舟云学术

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma

Published:2016-02-02 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Qin Chao,Cao Qiang,Li Pu,Wang Shangqian,Wang Jian,Wang Meilin,Chu Haiyan,Zhou Liqun,Li Xuesong,Ye Dingwei,Zhang Hailiang,Huang Yiran,Dong Baijun,Sun Xiaofeng,Zou Qing,Cai Hongzhou,Sun Lijiang,Zhu Jian,Liu Fade,Ji Junbiao,Cui Li,Wang Xiaoxiang,Zhou Hai,Zhao Hu,Wu Bin,Chen Jianchun,Jiang Minjun,Zhang Zhengdong,Shao Pengfei,Ju Xiaobing,Yin Changjun

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep20089.pdf

Reference20 articles.

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics. CA Cancer J Clin 63, 11–30 (2013).

2. Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N Engl J Med 353, 2477–90 (2005).

3. Drucker, B. J. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31, 536–45 (2005).

4. Law, T. M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824–32 (1995).

5. Baldewijns, M. M. et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221, 125–38 (2010).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of VEGFR1, VEGFR2 and VEGFR3 polymorphisms with esophageal cancer risk: a case–control study;Egyptian Journal of Medical Human Genetics;2024-08-09

2. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05

3. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy;Genes;2024-01-28

4. Association of VEGFR1, VEGFR2 and VEGFR3 Polymorphisms with Esophageal Cancer Risk: A Case- Control Study;2024-01-01

5. The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors;Drug Metabolism and Disposition;2023-09-29